Announcements
- Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
- Basilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma Foundation
- Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
- Starke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus
- Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
- Basilea berichtet über Präsentation neuer Daten zu Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2024
- Basilea shareholders approve all proposals of the board of directors at the annual general meeting
- Basilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des Verwaltungsrats
- Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
- Basilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-Wirkstoffklasse
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 32.30 |
Low | 32.30 |
Bid | -- |
Offer | -- |
Previous close | 32.30 |
Average volume | -- |
---|---|
Shares outstanding | 13.17m |
Free float | 13.16m |
P/E (TTM) | 45.30 |
Market cap | 522.84m CHF |
EPS (TTM) | 0.8765 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019 14:58 BST.
More ▼